logo
Finwire

Finwire

Analysguiden sees increased potential for Alzecure

Analysguiden sees increased potential for the research company Alzecure following several licensing deals and a strengthened cash position of SEK 232 million. This is stated in a commissioned analysis.

The research house assesses that the strong cash position gives Alzecure the opportunity to advance the pain project ACD137 into the clinical stage, which could create value. At the same time, the company is seeking a partner for the pain project ACD440, while an update on the next development step for the licensed-out Alzheimer’s project ACD856 is expected from Quantumcell.

Analysguiden expects ACD856 to enter Phase 2a in 2027, but emphasizes that the timeline is uncertain. The Phase 2a results from Roche’s Alzheimer’s project nivegacetor, which is relevant to Alzecure’s licensed-out project ACD680, may also not be available until next year.

The analysis reiterates the fair value for Alzecure at SEK 10.3.

Share this post

Verifierad av MonsterInsights